SCHEMBL427876

SCHEMBL427876

CC1(C)COCN1C(=O)n1cnc(-c2ccccc2)c1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 3/20 0.39
LMNA P02545 1/20 0.38
GABRA5 P31644 1/20 0.36
KDM4E B2RXH2 3/20 0.35
ALDH1A1 P00352 3/20 0.35
GAA P10253 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
CYP1A2 P05177 2/20 0.35
HPGD P15428 2/20 0.35
HSD17B10 Q99714 2/20 0.35
TSHR P16473 2/20 0.35
GLA P06280 2/20 0.35
CYP2C9 P11712 1/20 0.35
CASP1 P29466 1/20 0.35
CASP7 P55210 1/20 0.35
PTGS2 P35354 3/20 0.34
GRM5 P41594 2/20 0.33
POLB P06746 2/20 0.32
CYP2C19 P33261 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL427537 0.87 GABRA5 (0.38) CNR2LMNAGABRA5KDM4EALDH1A1
SCHEMBL427139 0.80 CNR2 (0.37) CNR2KDM4EALDH1A1GAASMN1; SMN2
SCHEMBL427478 0.76 HTT (0.55) LMNAKDM4EALDH1A1GAASMN1; SMN2
SCHEMBL425991 0.74 ALDH1A1 (0.40) CNR2LMNAGABRA5KDM4EALDH1A1
SCHEMBL427872 0.74 ALDH1A1 (0.36) CNR2GABRA5KDM4EALDH1A1GAA
SCHEMBL427458 0.68 KDM4E (0.53) CNR2KDM4EALDH1A1GAASMN1; SMN2
SCHEMBL427118 0.67 DPP4 (0.40) CNR2LMNAKDM4EALDH1A1GAA
SCHEMBL425856 0.67 CNR2 (0.39) CNR2LMNAKDM4EALDH1A1GAA
SCHEMBL425972 0.66 KDM4E (0.36) KDM4EALDH1A1GAASMN1; SMN2CYP1A2
SCHEMBL425830 0.66 KCNMA1 (0.36) CNR2GABRA5KDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
WO-2010074588-A2 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 CNR2 9/4885LMNA 2523/4885GABRA5 741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.